NCT04606394View on ClinicalTrials.gov

Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 2, 2020

Primary Completion Date

December 15, 2021

Study Completion Date

December 15, 2021

Conditions
COPD
Interventions
DRUG

Trelegy Ellipta 100/62.5/25Mcg Inh 30D

Administration of Trelegy in all patients

DRUG

Ventolin 90Mcg/Actuation Inhalation Aerosol

2 hours after the administration of Trelegy, administer Ventolin in all patients

Trial Locations (1)

48336

Pulmonary Research Institute of Southeast Michigan, Farmington Hills

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Pulmonary Research Institute of Southeast Michigan

OTHER

NCT04606394 - Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD | Biotech Hunter | Biotech Hunter